이중·다중특이 항체
성장
한 분자로 두 개 이상의 표적에 동시에 결합하는 항체. 면역세포와 암세포를 잇는 T세포 관여자(TCE)가 대표적.
전망 혈액암에서 검증된 뒤 고형암으로 진입 중. 삼중특이·조건부 활성화로 안전성을 높이는 방향.
개발 기업
최신 연구
전체 →Expert opinion on emerging drugs
Claudin-6 as a potential target in the treatment of ovarian cancer: a review of emerging drugsExpert opinion on biological therapy
비소세포폐암에 대한 항체-약물 결합체 기반 병용 치료 전략의 진전bioRxiv (프리프린트)
Integrating activation-induced costimulation and cytokine signals enhance TCR-based cell therapiesbioRxiv (프리프린트)
Engineered endothelial cell grafts form functional anastomoses and enable recruitment of intravenously delivered human T cells in CAM tumor modelsESMO open
Next-generation precision oncology in microsatellite stable colorectal cancer: integrated targeting beyond RAS and RAFEJHaem
Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real-World Case SeriesAnnals of hematology
Multidisciplinary approach to managing GPRC5D-related adverse events in relapsed or refractory multiple myeloma patientsBiotechnology and bioengineering
Purification of Advanced Therapeutics by Flow-Through Pseudo-Affinity Chromatography: Bi-Specific mABs, Fc Fusion Proteins, and Adeno-Associated VirusesBone research
Bispecific antibody against sclerostin and DKK1 improves bone health and reduces bone marrow adipose tissue accumulation in experimental chronic kidney diseaseMolecular biology reports
Immunotherapeutic strategies for castration-resistant prostate cancer: A systematic review of mechanisms, clinical advances and emerging approachesbioRxiv (프리프린트)
The CD19-4-1BBL antibody fusion protein unleashes the immune system against high-risk chronic lymphocytic leukemiaClinical chemistry
Characterization of the Migration Profile of 36 Therapeutic Monoclonal Antibodies in Serum Protein Electrophoresis and Immunofixation
진행 중 임상
전체 →- 2상모집 예정Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
- 1/2상모집 중First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
- 1/2상모집 중Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
- 2상모집 중Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
- 3상모집 중A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- 1/2상모집 중A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- 3상모집 중A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- 단계 미표기모집 예정ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
- 2상모집 중Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
- 1상모집 중Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
- 2상모집 중Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
- 2상모집 중Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.